1. Home
  2. LZB vs CAPR Comparison

LZB vs CAPR Comparison

Compare LZB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo La-Z-Boy Incorporated

LZB

La-Z-Boy Incorporated

N/A

Current Price

$33.92

Market Cap

1.4B

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$30.71

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LZB
CAPR
Founded
1927
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
1994
2011

Fundamental Metrics

Financial Performance
Metric
LZB
CAPR
Price
$33.92
$30.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$42.50
$41.38
AVG Volume (30 Days)
372.3K
921.3K
Earning Date
05-18-2026
01-01-0001
Dividend Yield
2.80%
N/A
EPS Growth
N/A
N/A
EPS
1.65
N/A
Revenue
$2,349,433,000.00
$22,270,465.00
Revenue This Year
$1.89
N/A
Revenue Next Year
$2.09
$17,308.50
P/E Ratio
$20.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.03
$4.30
52 Week High
$44.49
$40.37

Technical Indicators

Market Signals
Indicator
LZB
CAPR
Relative Strength Index (RSI) 34.73 66.95
Support Level $32.35 $22.09
Resistance Level $39.84 $40.37
Average True Range (ATR) 1.24 1.84
MACD -0.19 0.17
Stochastic Oscillator 26.54 92.68

Price Performance

Historical Comparison
LZB
CAPR

About LZB La-Z-Boy Incorporated

La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: